1. Home
  2. NWGL vs CYTH Comparison

NWGL vs CYTH Comparison

Compare NWGL & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NWGL
  • CYTH
  • Stock Information
  • Founded
  • NWGL 2008
  • CYTH 1990
  • Country
  • NWGL Macau
  • CYTH United States
  • Employees
  • NWGL N/A
  • CYTH N/A
  • Industry
  • NWGL
  • CYTH Biotechnology: Pharmaceutical Preparations
  • Sector
  • NWGL
  • CYTH Health Care
  • Exchange
  • NWGL Nasdaq
  • CYTH Nasdaq
  • Market Cap
  • NWGL 19.9M
  • CYTH 20.4M
  • IPO Year
  • NWGL 2023
  • CYTH N/A
  • Fundamental
  • Price
  • NWGL $1.30
  • CYTH $0.80
  • Analyst Decision
  • NWGL
  • CYTH Buy
  • Analyst Count
  • NWGL 0
  • CYTH 3
  • Target Price
  • NWGL N/A
  • CYTH $0.95
  • AVG Volume (30 Days)
  • NWGL 8.5K
  • CYTH 55.3K
  • Earning Date
  • NWGL 11-29-2024
  • CYTH 11-14-2024
  • Dividend Yield
  • NWGL N/A
  • CYTH N/A
  • EPS Growth
  • NWGL N/A
  • CYTH N/A
  • EPS
  • NWGL N/A
  • CYTH N/A
  • Revenue
  • NWGL $21,707,613.00
  • CYTH $870,725.00
  • Revenue This Year
  • NWGL N/A
  • CYTH N/A
  • Revenue Next Year
  • NWGL N/A
  • CYTH $24.49
  • P/E Ratio
  • NWGL N/A
  • CYTH N/A
  • Revenue Growth
  • NWGL N/A
  • CYTH N/A
  • 52 Week Low
  • NWGL $1.04
  • CYTH $0.55
  • 52 Week High
  • NWGL $21.97
  • CYTH $2.12
  • Technical
  • Relative Strength Index (RSI)
  • NWGL 54.56
  • CYTH 67.47
  • Support Level
  • NWGL $1.09
  • CYTH $0.55
  • Resistance Level
  • NWGL $1.35
  • CYTH $0.72
  • Average True Range (ATR)
  • NWGL 0.08
  • CYTH 0.07
  • MACD
  • NWGL 0.02
  • CYTH 0.02
  • Stochastic Oscillator
  • NWGL 82.26
  • CYTH 92.59

About NWGL Nature Wood Group Limited

Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber, recycled charcoal, synthesized charcoal, machine-made charcoal, and essential oils. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers. Geographically, the company generates a majority of its revenue from China.

About CYTH Cyclo Therapeutics Inc.

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

Share on Social Networks: